Massive cut facing India's 'theoretical' Glivec price
This article was originally published in Scrip
Executive Summary
India's latest drug price control measures could throw up a potentially peculiar situation for Novartis's anticancer, Glivec (imatinib), even as the Swiss multinational has probably yet to fully recover from the setback of April this year when the Supreme Court rejected a patent claim for the product in the country.